RxDoctor Payments Data

Rhonda White, NP

Family · Odessa, TXNPI 1447296884

Payments from drug & device makers

$670in general payments, 2019–2025

Across 21 payments — averaging $31.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$170
  • GSK$140
  • Sanofi$92
  • Lilly USA, LLC$85
  • Johnson & Johnson$78
  • Boehringer Ingelheim$38
  • plus $67 from 3 others

What the payments were for

  • Food & beverage$50075%
  • Education$17025%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$670 in reported general payments places this provider in the 60th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$20,371
Medicare patients
128
Services billed
666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide90$100,691
RybelsusSemaglutide16$31,010
JardianceEmpagliflozin37$29,193
TrulicityDulaglutide14$24,065
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$20,546
EliquisApixaban27$18,840
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog39$18,202
MounjaroTirzepatide15$17,667
FarxigaDapagliflozin Propanediol21$15,770
JanuviaSitagliptin Phosphate11$15,445
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog27$11,480
MyrbetriqMirabegron11$6,901
Combivent RespimatIpratropium/Albuterol Sulfate14$6,773
Lantus SolostarInsulin Glargine,hum.Rec.Anlog40$6,031
Novolog FlexpenInsulin Aspart25$5,445

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$20$131,701106 claims
Lilly USA, LLCTrulicity, Mounjaro$85$41,73329 claims
Boehringer IngelheimJardiance, Combivent Respimat$38$35,96651 claims
GSKTrelegy Ellipta$140$20,54629 claims
PfizerEliquis$18$18,84027 claims
Astellas Pharma US IncMyrbetriq$170$6,90111 claims
AbbVieArmour Thyroid$30$1,23616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 15,456 family providers in Texas.

Other family in Odessa

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →